Q2 2025 Nykode Therapeutics ASA Earnings Call Transcript
Key Points
- Nykode Therapeutics AS (VACBF) announced key data from their VB10.NEO program, demonstrating robust and durable immune responses across multiple tumor types.
- The VB10.16 program showed a favorable safety profile, with all doses cleared by the trial safety group.
- The company recorded a net profit of $900,000 in Q2 2025, a significant improvement from a net loss of $7.3 million in Q2 2024.
- Nykode has a strong cash position of $70 million, providing a solid financial foundation for future developments.
- The company plans to initiate a Phase II randomized clinical trial for VB10.16, expected to deliver significant data within their cash runway.
- Total revenue and other income decreased to $200,000 in Q2 2025 from $600,000 in Q2 2024, primarily due to reduced revenue from Genentech and Regeneron.
- Nykode has removed collaboration programs with Regeneron from their updated strategy and financial forecasts.
- The company underwent significant restructuring and prioritization efforts to control cash burn, indicating previous financial strain.
- There is uncertainty regarding the outcome of a pending tax case, which could impact future cash runway projections.
- The competitive landscape for individualized neoantigen therapies is challenging, with several key peer readouts expected in the next 18 months.
Greetings, and welcome to the Nykode Therapeutics second quarter 2025 strategy update and results webcast. (Operator Instructions) As a reminder, this conference is being recorded.
It's now my pleasure to turn the call over to CEO, Michael Engsig. Please go ahead, Michael.
Thank you very much, Kevin. And also from my side, a very warm welcome to everybody to this Q2 webcast and not least our long-anticipated strategy update from Nykode. Before moving on, I just want to remind every one of you of our forward-looking statements. We assume you are familiar with those. And on that basis, I'll quickly move on.
As usual, I am very pleased to have with me here today, Agnete Fredriksen, our Co-Founder and CSO; and Harald Gurvin, our CFO. Before moving into the strategy update, which I believe you've all been waiting for at this time point here, we'll adjust very quickly or briefly review the key highlights from our Q2 report, which was also announced or issued this morning here. And
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
